


**2026 eCQM Flow**  
**eCQM Identifier: CMS129v15**


**NOTE:** This flow diagram represents an overview of population criteria requirements. **Refer to the eCQM specification for a complete list of data elements included in this measure and required for submission.**

**Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients**

Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low (or very low) risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy who did not have a bone scan performed at any time since diagnosis of prostate cancer

**This eCQM is a patient-based measure**





**Performance Rate =**

**Sample Calculation**

$$\frac{\text{Numerator (a = 40 patients)}}{\text{Denominator (b = 100 patients) - Denominator Exceptions (c = 20 patients)}} = \frac{40}{80} = 50\%$$

**eCQM Identifier: CMS129v14****eCQM Title: Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients**

**NOTE:** This flow diagram represents an overview of population criteria requirements. Refer to the eCQM specification for a complete list of data elements included in this measure and required for submission.

**Description:** Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low (or very low) risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy who did not have a bone scan performed at any time since diagnosis of prostate cancer.

**This eCQM is a patient-based measure.**

**eCQM Flow Narrative****Initial Population**

Start by identifying the Initial Population, all patients, regardless of age, with a diagnosis of prostate cancer that overlaps the measurement period.

**Denominator**

The Denominator criteria further constrain the Initial Population to patients whose first prostate cancer treatment (e.g., interstitial prostate brachytherapy, or external beam radiotherapy to the prostate, or radical prostatectomy) occurred during the measurement period and who are at low (or very low) risk of recurrence (with a prostate cancer staging tumor size T1a to T2a, a PSA test result of less than 10 nanograms per milliliter, and a Gleason score of less than or equal to 6). In the sample calculation provided at the end of the eCQM flow, the Denominator is equal to 100 patients.

**Numerator**

The Numerator criteria identify a subset of the Denominator population by including patients who did not have a bone scan performed after diagnosis of prostate cancer and before the end of the measurement period. In the sample calculation provided at the end of the eCQM flow, the Numerator is equal to 40 patients.

**Denominator Exceptions**

The Denominator Exceptions criteria identify patients from the Denominator that did not meet the Numerator population criteria due to diagnosis of pain warranting further investigation for prostate cancer, salvage therapy performed after prostate cancer diagnosis, or bone scan performed with documented reason. In the sample calculation provided at the end of the eCQM flow, the Denominator Exceptions are equal to 20 patients.

**Sample Calculation**

A sample calculation is provided to help determine how the measure performance rate is derived. The measure performance rate is calculated by dividing the Numerator (total equals 40

patients) by the difference between the Denominator (total equals 100 patients) and the Denominator Exceptions (total equals 20 patients), which is equal to a score of 50 percent.